Tech Transfer eNews Blog

U of Sheffield start-up is developing novel treatment for various cancers


By Jesse Schwartz
Published: September 16th, 2020

A University of Sheffield (TUOS) spinout is developing a treatment that could improve the life expectancy and quality of life for patients with cancers such as pancreatic and relapsed breast cancer.

Modulus Oncology is building on more than 12 years of TUOS research and has attracted substantial grant funding to develop and commercialize its novel treatment.

“Previous scientific research in areas such as pancreatic cancer and relapsed breast cancers have focused on a hormone called adrenomedullin, which acts through two different types of receptors: one which helps regulate our blood pressure, and the other which helps cancer cells communicate with each other, allowing them to grow and spread,” explains Tim Skerry, professor at TUOS and chief scientific officer at Modulus Oncology.

“Our pioneering approach focuses on novel drug molecules, known as adrenomedullin-2 receptor antagonists, which are able to block the hormone’s communication without adversely affecting the control of blood pressure and other vital body processes,” Skerry says.

Alan Wise, CEO of Modulus, comments, “The team at the University of Sheffield have performed some truly pioneering research here, and I am delighted to be helping Modulus Oncology take this vital work towards clinical testing. Our goal is to demonstrate benefit for cancer patients as well as growing a successful UK biotech company.”

The start-up is currently in discussions with various life science investors to raise seed and Series A funding for human clinical trials that, if successful, would help accelerate the drug to the marketplace.

Source: GlobeNewswire

Posted under: Tech Transfer e-News

Twitter Facebook Linkedin Pinterest Email

No Comments so far ↓

There are no comments yet...Kick things off by filling out the form below.

Leave a Comment